CAFs inhibit the response of MET-amplified NSCLC cells to MET kinase inhibitors in an HGF-dependent manner, with HGF activating the phosphorylation of MET and EGFR via signaling pathways.78 The gene discussed is MET; the disease is non-small cell lung carcinoma.